Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.65 |
| ▸ | PHLPP1 | O60346 | 2/20 | 0.65 |
| ▸ | ILK | Q13418 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441388 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL3270839 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL29393858 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL19659847 | 0.90 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4193356 | 0.87 | AKT1 (0.60) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5772966 | 0.86 | AKT1 (0.61) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4780480 | 0.85 | ALOX5 (0.51) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL14580950 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL18212526 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771546 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170059553-A1 | BIOMARKER FOR DIAGNOSIS OF IRRITABLE BOWEL SYNDROME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-02 | — | — | US | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| EP-1634958-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CHROMAN-CARBOXYLATE | MITSUBISHI GAS CHEMICAL CO (JP) | 2009-02-18 | — | — | EP | claimed |
| EP-1199075-B1 | The use of gamma-CEHC as antioxidants | EISAI R&D MAN CO LTD (JP) | 2007-04-18 | — | — | EP | claimed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | claimed |
| US-7119117-B2 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | GALILEO PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | claimed |
| US-7081476-B2 | Tocopherol enriched compositions for reducing IL6 levels | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-25 | — | — | US | claimed |
| US-20060141591-A1 | Method for producing optically active chroman-carboxylate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-06-29 | — | — | US | claimed |
| EP-1634958-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CHROMAN-CARBOXYLATE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-03-15 | — | — | EP | claimed |
| US-6555575-B2 | Administering one of 2,5,7,8-tetramethyl-2-(beta-carboxyethyl)-6-hydroxychromane, or 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychromane, as antioxidants; arteriosclerosis | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2003-04-29 | — | — | US | claimed |
| US-20030027857-A1 | Tocotrienol derivative, process for producing the same and gamma-CEHC delivering agent | JIRO TAKATA (JP) | 2003-02-06 | — | — | US | claimed |
| US-20020165268-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J (US) | 2002-11-07 | — | — | US | claimed |
| EP-1140065-A4 | USE OF GAMMA-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-ALPHA IN THE TREATMENT OF DISEASE | UNIV LOMA LINDA MED (US) | 2002-10-16 | — | — | EP | claimed |
| EP-1199075-A2 | Use of vitamine E metabolites alpha-CEHC and gamma-CEHC as antioxidants | Eisai Co., Ltd. (JP) | 2002-04-24 | — | — | EP | claimed |
| US-20020040053-A1 | Antioxidant containing vitamin E metabolite | MITSUBISHI-CHEMICAL FOODS CORPORATION (JP) | 2002-04-04 | — | — | US | claimed |
| EP-1140065-A1 | USE OF GAMMA-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-ALPHA IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2001-10-10 | — | — | EP | claimed |
| US-6242479-B1 | ADMINISTERING ORALLY OR PARENTALLY TO PREVENT CARDIOVASCULAR, NERVOUS SYSTEM, OR BRAIN DISORDERS; ANTIOXIDANTS, ANTICOAGULANTS, HYPOTENSIVE AGENTS; ATHEROSCLEROSIS | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2001-06-05 | — | — | US | claimed |
| WO-2000035444-A1 | USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-06-22 | — | — | WO | claimed |
| US-6048891-A | ADMINISTERING MIXTURES WITH 6-HYDROXY-2,7,8-TRIMETHYL-CHROMAN-2-PROPANOIC ACID FOR TREATMENT OF CARDIOVASCULAR AND KIDNEY DISORDERS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20020165268-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, LPO | AKT1 3599/4885PDPK1 4172/4885PHLPP1 3792/4885 |
| US-20030027857-A1 | Tocotrienol derivative, process for producing the same and gamma-CEHC delivering agent | TTPA, CYP46A1, DHCR24 | AKT1 4617/4885PDPK1 4709/4885PHLPP1 3663/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885PDPK1 2127/4885PHLPP1 2278/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | AKT1 3502/4885PDPK1 2127/4885PHLPP1 2278/4885 |
| US-20020040053-A1 | Antioxidant containing vitamin E metabolite | TTPA, TXNRD2, CYP27B1 | AKT1 3874/4885PDPK1 4156/4885PHLPP1 3970/4885 |
| US-20060141591-A1 | Method for producing optically active chroman-carboxylate | ACMSD, ADH5, ADH1C | AKT1 1956/4885PDPK1 1236/4885PHLPP1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.